News und Analysen
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a
ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
Building upon its flagship Endosafe® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board
New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic
Premier, Inc. to Report Fiscal 2024 Second-Quarter Results and Host Conference Call on February 6, 2024
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 second quarter on Tuesday, February 6, 2024, at approximately 6:30 a.m. ET. The company will
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Acadia Healthcare and Ascension Seton Form Joint Venture to Expand Behavioral Health Services in Austin
Ascension Seton and Acadia Healthcare announced today that the two organizations have formed a joint venture to expand access to behavioral healthcare in Austin, Texas, and surrounding communities
Acadia Healthcare Enters Into a Joint Venture Partnership With Ascension Seton to Expand Behavioral Health Services in Austin, Texas
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture partnership with Ascension Seton, one of the leading, integrated healthcare systems in Austin
ICON Issues Financial Guidance for Full Year 2024
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2024. For the
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. PST (1:30
LivaNova to Wind Down Advanced Circulatory Support Business Unit
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS)
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023. Novocure is a global oncology company
Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the